InMed Posts $0.42 Fiscal Q1 Loss Per Share, Forecasts Cash Into Mid-November

InMed Pharmaceuticals posted a net loss of $2,330,778 for its fiscal 2027 first quarter and forecast that available cash would cover planned costs into mid-November, depending on spending and the timing of its proposed merger with Mentari Therapeutics. For the three months ended Sept. 30, 2026, basic and diluted net loss was $0.42 per share. That total included a $0.36 loss per share from continuing operations and a $0.06 loss from discontinued operations. In the year-earlier quarter, the total loss was $0.44 per share and net loss was $1,726,899.

Source: TokenPost